Date: 2016-09-27
Type of information: Collaboration agreement
Compound:
Company: Gilead Sciences (USA - CA) World Health Organization
Therapeutic area: Parasitic diseases
Type agreement: collaboration
Action mechanism:
Disease: visceral leishmaniasis
Details: * On September 27, 2016, Gilead Sciences announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis. As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat visceral leishmaniasis in key endemic countries, including Bangladesh , Ethiopia , India , Nepal , South Sudan and Sudan . Gilead's support of WHO's leishmaniasis control program began in 1992. In December 2011 , Gilead expanded its partnership by donating approximately 445,000 vials of AmBisome® to treat more than 50,000 people over five years and to expand the number of VL treatment centers from fewer than 15 in 2011 to more than 160 in 2015. Gilead's funding will enable WHO to expand and reinforce leishmaniasis surveillance and control efforts in highly endemic areas, including creating a sustainable infrastructure to improve diagnosis and treatment of VL. Gilead's medicine donation will be distributed by WHO as determined by a group of experts appointed by WHO.
Financial terms:
Latest news:
